Foghorn Therapeutics Inc. - Common Stock (FHTX)

Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program.

FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Foghorn Therapeutics shares are trading higher by 44.8% Thursday. The company announced that Eli Lilly has chosen FHD-909 for clinical development.

Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms.

Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market trading.

Foghorn Therapeutics Inc (NASDAQ: FHTX) announced the data from the Phase 1 dose escalation safety study of FHD-286 in 

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday. The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16. The S&P 500, also fell, dropping, 0.01% to 4,132.91.

Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment.

U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P 500, also fell, dropping, 0.32% to 4,120.38.